Novartis AG . v. Torrent Pharms. Ltd.
Novartis AG . v. Torrent Pharms. Ltd., 2016-1352
In an appeal from the Final Written Decision of the United States Patent and Trademark Office, Patent Trial and Appeal Board in two consolidated inter partes review (IPR) proceedings of a patent that relates to a solid pharmaceutical composition suitable for oral administration which is useful for the treatment of certain autoimmune diseases such as multiple sclerosis, the Board’s decision, that all original claims of the ’283 patent and plaintiff’s proposed substitute claims unpatentable as obvious, is affirmed over a series of plaintiff’s challenges to the Board’s analysis of the evidence and ultimate determination of unpatentability.
- Published 2017/04/12
- United States Federal Circuit